Deferoxamine

Reference work entry
First Online:

Abstract

Deferoxamine is a chelator used for acutely ill iron-poisoned patients. It can also be used as an aluminum chelator and in the treatment of transfusional iron overload states. Its use in critically-ill patients is, however, almost always confined to patients with acute iron overdose. The treatment of acute iron toxicity is discussed in detail in the “Iron” chapter. This chapter focuses on the clinical pharmacology of deferoxamine for the treatment of acute iron poisoning.

Keywords

Deferoxamine Iron Aluminum Iron overdose Ferrioxamine Transferrin Yersinia sepsis Yersinia enterocolitica 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Keberle H. The biochemistry of desferrioxamine and its relation to iron metabolism. Ann N Y Acad Sci. 1964;119:758–68.CrossRefPubMedGoogle Scholar
  2. 2.
    Moeschlin S, Schnider U. Treatment of primary and secondary hemochromatosis and acute iron poisoning with a new potent iron eliminating agent (desferrioxamine-B). N Engl J Med. 1963;269:57–66.CrossRefGoogle Scholar
  3. 3.
    Westlin W. Deferoxamine in the treatment of acute iron poisoning: clinical experiences with 172 children. Clin Pediatr. 1966;5:531–5.CrossRefGoogle Scholar
  4. 4.
    Westlin W. Deferoxamine as a chelating agent. Clin Toxicol. 1971;4:597–602.CrossRefPubMedGoogle Scholar
  5. 5.
    Hershko C, Konijn AM, Ling G. Iron chelators for thalassemia. Br J Haematol. 1998;101:399–406.CrossRefPubMedGoogle Scholar
  6. 6.
    Cabantchik ZL, Milgram P, Glickstein H, et al. A method for assessing iron chelation in membrane model systems and in living mammalian cells. Anal Biochem. 1995;233:221–7.CrossRefGoogle Scholar
  7. 7.
    Zannineli G, Glickstein H, Breuer W, et al. Chelation and mobilization of cellular iron by different classes of chelators. Mol Pharmacol. 1997;51:842–52.Google Scholar
  8. 8.
    Pollack S, Vanderhoff G, Lasky F. Iron removal from transferrin – an experimental study. Biochim Biophys Acta. 1977;497:481–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Breuer W, Ermers MJ, Pootrakul P, et al. Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy. Blood. 2001;97:792–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Barry M, Flynn DM, Letsky EA, et al. Long-term chelation therapy in thalassemia major: effect on liver iron concentration, liver histology, and clinical prograss. BMJ Clin Res. 1974;2:16–20.CrossRefGoogle Scholar
  11. 11.
    Porter JB. Deferoxamine pharmacokinetics. Semin Hematol. 2001;38:63–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Bentur Y, Koren G, Klein J, et al. Pharmacokinetics of deferoxamine with and without iron load. Vet Hum Toxicol. 1989;31:156–7.PubMedGoogle Scholar
  13. 13.
    Lee P, Mohammed N, Abeysinghe RD, et al. Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemia patients. Drug Metab Dispos. 1993;21:640–4.PubMedGoogle Scholar
  14. 14.
    Singh S, Hider RC, Porter JB. Separation and identification of desferrioxamine and its iron chelating metabolites by high-performance liquid chromatography and fast atom bombardment mass spectrometry. Anal Biochem. 1990;187:1–8.CrossRefGoogle Scholar
  15. 15.
    Singh S, Mohammed N, Ackerman R, et al. Quantification of desferrioxamine and its iron chelating metabolites by high-performance liquid chromatography and simultaneous ultraviolet–visible/radioactive detection. Anal Biochem. 1992;203:116–20.CrossRefPubMedGoogle Scholar
  16. 16.
    Allain P, Mauras Y, Chaleil D, et al. Pharmacokinetics and renal elimination of desferrioxamine and ferrioxamine in healthy subjects and patients with haemochromatosis. Br J Clin Pharmacol. 1987;24:207–12.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Peter G, Keberle M, Schmid K. Distribution and renal excretion of desferrioxamine and ferrioxamine in the dog and in the rat. Biochem Pharmacol. 1966;15:93–109.CrossRefGoogle Scholar
  18. 18.
    Richardson JR, Sugerman DL, Hulet WH. Extraction of iron by chelation with desferrioxamine and hemodialysis. Clin Res. 1967;15:368.Google Scholar
  19. 19.
    Banner Jr W, Vernon DD, Ward RM, et al. Continuous arteriovenous hemofiltration in experimental iron intoxication. Crit Care Med. 1989;17:1187–90.CrossRefPubMedGoogle Scholar
  20. 20.
    Ceriati F, Pomponi M, Cavicchioni C, et al. Continuous intra-venous (CIV) infusion of deferoxamine (DF) in a hemodialysed patient with transfusion or siderosis (Letter). Int J Artif Organs. 1981;4:409.Google Scholar
  21. 21.
    McGonigle RJS, Keogh AM, Weston MJ, et al. Iron status in chronic hemodialysis patients: treatment of transfusional iron overload with desferrioxamine. Dial Transplant. 1984;13:214.Google Scholar
  22. 22.
    Hilfenhaus M, Koch KM, Bechstein PB, et al. Therapy and monitoring of hypersiderosis in chronic renal insufficiency. Contrib Nephrol. 1984;38:167–74.CrossRefPubMedGoogle Scholar
  23. 23.
    Rayburn WF, Donna SM, Wulf ME. Iron overdose during pregnancy: successful therapy with deferoxamine. Am J Obstet Gynecol. 1983;147:717–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Blanc P, Hryhorczuk D, Danel I. Deferoxamine treatment of acute iron intoxication in pregnancy. Obstet Gynecol. 1984;64:125–45.CrossRefGoogle Scholar
  25. 25.
    Thomas RM, Skalicka AE. Successful pregnancy in transfusion-dependent thalassaemia. Arch Dis Child. 1980;55:572–4.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Singer ST, Vichinsky EP. Deferoxamine treatment during pregnancy: is it harmful? Am J Hematol. 1999;60:24–6.CrossRefPubMedGoogle Scholar
  27. 27.
    Martin K. Successful pregnancy in β-thalassaemia major. Aust Pediatr J. 1983;19:182–3.Google Scholar
  28. 28.
    Curry SC, Bond GR, Raschke R, et al. An ovine model of maternal iron poisoning in pregnancy. Ann Emerg Med. 1990;19:632–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Bentur Y, McGuigan M, Koren G. Deferoxamine (desferrioxamine) new toxicities for an old drug. Drug Saf. 1991;6:37–46.CrossRefPubMedGoogle Scholar
  30. 30.
    Howland MA. Risks of parenteral deferoxamine. J Toxicol Clin Toxicol. 1996;34:491–7.CrossRefPubMedGoogle Scholar
  31. 31.
    Whitten CF, Gibson GW, Good MH, et al. Studies in acute iron poisoning: I. Desferrioxamine in the treatment of acute iron poisoning. Pediatrics. 1965;36:322–35.PubMedGoogle Scholar
  32. 32.
    Brunner H, Peters G, Jaques R. Wirkungen ven desferrioxamine-methansulfonat auf kreislauf und nierenfunktion. Helv Physiol Pharmacol Acta. 1963;21:C3–6.Google Scholar
  33. 33.
    Koren G, Bentur Y, Strong D, et al. Acute changes in renal function associated with deferoxamine therapy. Am J Dis Child. 1989;143:1077–80.PubMedGoogle Scholar
  34. 34.
    Tenenbein M. Benefits of parenteral deferoxamine for acute iron poisoning. J Toxicol Clin Toxicol. 1996;34:485–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Bentur Y, Koren G, Klein J, et al. Pharmacokinetics and nephrotoxicity of deferoxamine. Vet Hum Toxicol. 1988;30:371.Google Scholar
  36. 36.
    Scanderbeg AC, Izzi GC, Butturini A, et al. Pulmonary syndrome and intravenous high-dose desferrioxamine. Lancet. 1990;336:1511.CrossRefGoogle Scholar
  37. 37.
    Freedman MH, Grisaru D, Olivieri N, et al. Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions. Am J Dis Child. 1990;144:565–9.PubMedGoogle Scholar
  38. 38.
    Tenenbein M, Kowalski S, Sienko A, et al. Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning. Lancet. 1992;379:699–701.CrossRefGoogle Scholar
  39. 39.
    Douglas D, Smilkstein M. Deferoxamine-iron induced pulmonary injury and N-acetylcysteine. J Toxicol Clin Toxicol. 1995;33:495.Google Scholar
  40. 40.
    Rego EM, Neto EB, Simoes BP, Zago MA. Dose-dependent pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine (Letter). Am J Hematol. 1998;58:340–1.CrossRefPubMedGoogle Scholar
  41. 41.
    Melby K, Slordahal S, Gutteberg TJ, et al. Septicemia due to Yersinia enterocolitica after oral doses of iron. BMJ. 1982;285:487–8.CrossRefGoogle Scholar
  42. 42.
    Gallant T, Freedman MH, Velland H, et al. Yersinia sepsis in patients with iron overload treated with deferoxamine. N Engl J Med. 1986;314:1643.PubMedGoogle Scholar
  43. 43.
    Mofenson HC, Caraccio TR, Sharieff N. Iron sepsis: Yersinia enterocolitica septicemia possibly caused by an overdose of iron. N Engl J Med. 1987;316:1092–3.PubMedGoogle Scholar
  44. 44.
    Bouza A, Dominguez A, Meseguer M, et al. Yersinia enterocolitica septicemia. Am J Clin Pathol. 1980;74:404–9.CrossRefPubMedGoogle Scholar
  45. 45.
    Rabson AR, Halett AF, Koornhof HJ. Generalised Yersinia enterocolitica infection. J Infect Dis. 1975;131:447–51.CrossRefPubMedGoogle Scholar
  46. 46.
    Robins-Browne RM, Rabson AR, Koornhof HJ. Generalized infection with Yersinia enterocolitica and the role of iron. Contrib Microbiol Immunol. 1979;5:277–82.PubMedGoogle Scholar
  47. 47.
    Brock JH, Ng J. The effect of desferrioxamine on the growth of Staphylococcus aureus Yersinia enterocolitica and Streptococcus faecalis in human serum: uptake of desferrioxamine-bound iron. FEMS Microbiol Lett. 1983;2:439–42.CrossRefGoogle Scholar
  48. 48.
    Authanosiou A, Shepp MA, Nechles H. Anaphylactic reaction to deferoxamine. Lancet. 1977;2:616.CrossRefGoogle Scholar
  49. 49.
    Gevirtz NR, Wasserman LR. The measurement of iron and iron-binding capacity in plasma containing deferoxamine. J Pediatr. 1966;68:802–4.CrossRefPubMedGoogle Scholar
  50. 50.
    Helfer RE, Rogerson DO. The effect of deferoxamine on the determination of serum iron and iron-binding capacity. J Pediatr. 1966;68:804–6.CrossRefPubMedGoogle Scholar
  51. 51.
    Steinmetz WL, Glick MR, Oei TO. Modified aca method for determination of iron chelated by deferoxamine and other chelators. Clin Chem. 1980;26:1593–7.PubMedGoogle Scholar
  52. 52.
    Fine JS. Iron poisoning. Curr Probl Pediatr. 2000;30:71–90.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.School of PharmacyUniversity of California, San FranciscoSan FranciscoUSA

Personalised recommendations